The precise mechanisms of these dyslipidemias are uncertain, but likely result from alterations to insulin signaling caused by mTOR inhibition that subsequently inhibit the activity of lipases on circulating lipoproteins, and/or alterations in degradation of apolipoprotein B100 (51, 53, 54). This evidence concerns the gene INS and metabolic syndrome.